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Aztreonam for inhalation solution, challenges to drug approval and
integration into CF careMany new therapies are emerging for the treatment of CF. In
the last 2 years, six agents have been approved by the Food and
Drug Administration (FDA) and four agents have given an
opinion in favor of granting a marketing authorization by the
European Medicines Agency (EMA) representing dramatic
results from decades of investment in basic and clinical science.
In this month's journal, Assael and colleagues [13] present data
from a phase 3 open-label, randomized, parallel-group, active-
comparator non-inferiority trial comparing aztreonam for
inhalation solution (AZLI) and inhaled tobramycin nebulizer
solution (TNS). They concluded that AZLI demonstrated
statistical superiority in lung function and reduced acute
pulmonary exacerbations compared to TNS. This trial raises
some key issues in CF drug development. First, the role of
non-inferiority design strategies pose unique limitations.
Second, major regulatory bodies (FDA and EMA) are not
necessarily in alignment about non-inferiority trials. Third,
these new agents are very costly, adding considerably to
treatment costs.
Using an interesting design element this study included
co-primary endpoints: non-inferiority of AZLI for relative
change from baseline in FEV1% predicted at Day 28 and
superiority of AZLI for actual change from baseline in FEV1%
predicted compared to TNS across 3 treatment cycles [13].
Non-inferiority trial design is an increasingly common study
design allowing comparison of a new therapy to an existing
standard therapy (active comparator studies). Another option is
to conduct an equivalence study — equivalence is established
when clinically important differences favoring standard care are
ruled out [1]. These two study formats are often employed
when one has two agents (same indication), with the newer
agent having reduced toxicity profile or easier administration.
Of these designs, non-inferiority studies have become the
dominant design. A non-inferiority study is essentially a one
sided test of equivalence; the design will determine if new
treatment is worse by less than the non-inferiority margin
which is pre-specified [2]. A key challenge is deciding a priori
the non-inferiority margin. Assael and colleagues [13], set the
non-inferiority margin (non-inferiority primary aim) at 4%,
meaning if the 95% confidence interval lower boundary for the
treatment difference (AZLI–TNS) was N−4%, AZLI would be
deemed non-inferior to TNS. This margin should be determined1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.08.006on clinical grounds and published literature and will profoundly
affect sample size. Publication bias (not publishing negative
trials) can complicate the establishment of appropriate
non-inferior margins. The other significant challenge to
non-inferiority and equivalence studies [2,3], is investigators
cannot confirm that active control is still effective (the
constancy assumption). The literature notes examples of
waning of efficacy of approved medications over time; an
example includes antidepressants (nomifensine vs imipramine)
[4,5]. “Biocreep” occurs when non-inferiority sequential
comparisons are done in the setting of waning efficacy of
older medications [2,3]. Thus if TNS efficacy has diminished,
stating that the new therapy is no more than 4% FEV1%
predicted worse could mean that the new agent is ineffective
and even potentially harmful. This study and one prior study
provide data to suggest the efficacy of TNS has diminished;
FEV1% predicted changed by only +0.55% after 28 days of
TNS [13] in the current study and only +1% (95% CI: −1.2 to
3.7) in another recent study [6]. This is one reason why
non-inferiority studies may concern some regulatory bodies.
The current study was fortunate to not only show
non-inferiority of AZLI over TNS, but also demonstrated
superiority over TNS at study completion with a treatment
difference (AZLI–TNS) of 3.4% (p=0.02).
There are clear challenges to drug development for CF. The
EMA requests the following for drug development: randomized
active-controlled trials are mandatory with the requirement of
superiority with active control for mucolytic agents [7].
Blinding is desired when feasible [7]. The FDA prefers two
superiority blinded placebo-controlled randomized trials. While
the FDA accepts equivalence and non-inferiority, they can have
no more than 10% inferiority margin and should demonstrate
that ‘test’ treatment is effective or efficacious (would have
beaten placebo) [4,5,8,9]. These differences between study
design recommendations can complicate and add to the
expense of drug development in orphan diseases like CF; the
AZLI program conducted three phase 3 clinical trials towards
regulatory approval.
After agency approval, will health care systems be able to
deliver new drugs? The FDA and EMA approve new therapies
in the USA and in the European Union (EU) and influence
decisions by other independent national agencies. Theby Elsevier B.V. All rights reserved.
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in Europe is coordinated nationally. Funding of new therapies
varies considerably between countries even those within the EU
and in some cases within countries. This is particularly the case
where funding of health is split between different government
jurisdictions (e.g. Canada and Australia) or between private
medical insurance providers and government funding organi-
zations (e.g. USA). While, the FDA and EMA approved TNS
in 1997, its availability has been delayed in some parts of the
world. In Australia, the Therapeutic Goods Administration
approved TNS is early 2000, however IV tobramycin
preparations continued to be used during the decade until
funding by the government in 2011. Similarly, TNS has been
available in some Canadian provinces but in others IV solution
continues to be used, as it is in New Zealand.
AZLI has been approved by the FDA and EMA and is
currently available and funded in ~50% of EU countries and a
decision pending in others. Given its likely cost, its availability
is likely to be delayed in many parts of the world. In most
western European countries (including non-EU) out of pocket
expenses for CF therapies are relative small. For example, in
Italy all CF therapies are provided free of charge to the patient
with the Italian government paying the full cost. Similar,
systems operate in Scandinavia and Spain. In The Netherlands,
costs are paid by health insurance companies and membership
is compulsory, though if one is not working the premium is
paid by the government.
Funding models for CF care including drug therapy may
contribute to considerable variability in health care outcomes
and are likely to be a factor in poorer outcomes in patients from
Eastern Europe and those living in parts of the world where
funding for or access to health care is limited [10]. As many
new therapies are undergoing intense investigation, the drug
cost component of CF care is likely to increase in the coming
years and may contribute to further differences between
outcomes internationally. The current cost of ivacaftor is very
likely to be prohibitive in many other parts of the world. Similar
challenges and some early solutions have been seen in other
diseases states (e.g. antiretroviral treatment for HIV infection)
which are expensive and affect large populations in the
developed and developing worlds [11,12]. Learning from
other disease experiences will be important, as many new CF
therapies are likely to be submitted from approval in the
coming years.
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